Drug Approval | May 25, 2026
Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Clearance marks major shift beyond chemotherapy
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Subscribe To Our Newsletter & Stay Updated
